Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Significant Growth in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 144,900 shares, an increase of 23.1% from the June 30th total of 117,700 shares. Based on an average trading volume of 277,800 shares, the short-interest ratio is currently 0.5 days. Currently, 0.7% of the shares of the stock are sold short.

Xilio Therapeutics Trading Up 5.3 %

Shares of XLO stock opened at $1.01 on Monday. Xilio Therapeutics has a 1 year low of $0.49 and a 1 year high of $2.94. The firm’s 50 day moving average is $0.99 and its 200-day moving average is $0.92.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.29). Equities research analysts anticipate that Xilio Therapeutics will post -1.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC bought a new stake in Xilio Therapeutics, Inc. (NASDAQ:XLO) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned about 0.09% of Xilio Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.